Global Drug Delivery Partnering 2010-2015: Deal trends, players and financials


#149827

2474pages

Current Partnering

$ 3495

In Stock

The Global Drug Delivery Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.

The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,800 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format- by company A-Z, stage of development, deal type, therapy focus, and technology type- that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered- contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.

Key benefits

Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Drug Delivery deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Drug Delivery agreements with numerous real life case studies
Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
Identify most active Drug Delivery dealmakers since 2010
Insight into terms included in a Drug Delivery partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Drug Delivery Partnering Terms and Agreements includes:

Trends in Drug Delivery dealmaking in the biopharma industry since 2010
Analysis of Drug Delivery deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Drug Delivery deals
Access to Drug Delivery contract documents
Leading Drug Delivery deals by value since 2010
Most active Drug Delivery dealmakers since 2010

In Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,800 Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

 

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery partnering over the years
2.3. Big pharma drug delivery dealmaking activity
2.4. Big biotech drug delivery dealmaking activity
2.5. Most active drug delivery dealmakers
2.6 Drug delivery partnering by deal type
2.7. Drug delivery partnering by disease type
2.8. Partnering by drug delivery technology type
2.9. Average deal terms for drug delivery partnering
2.9.1 Drug delivery headline values
2.9.2 Drug delivery upfront payments
2.9.3 Drug delivery milestone payments
2.9.4 Drug delivery royalty rates
2.10. The anatomy of drug delivery partnering
2.11. Drug delivery or specialty pharma?
2.11.1. Is specialty pharma the only way for drug delivery?
2.11.2. Best practice for optimizing drug delivery program development
2.11.3. The anatomy of a drug delivery deal
2.11.3. a. Case study 1: Uluru – Oradisc – Oct 2012
2.11.3.b. Case study 2: Ohio State University – Microlin Bio – Sep 2013
2.11.3.c. Case study 3: Endo Pharmaceuticals – BioDelivery Sciences – Jan 2012

Chapter 3 – Leading drug delivery deals

3.1. Introduction
3.2. Top drug delivery deals by value

Chapter 4 – Big pharma drug delivery deals

4.1. Introduction
4.2. How to use big pharma drug delivery partnering deals
4.3. Big pharma drug delivery partnering company profiles

Chapter 5 – Big biotech drug delivery deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech drug delivery partnering company profiles

Chapter 6 – Drug delivery partnering contracts directory

6.1. Introduction
6.2. Company A-Z
6.3. By deal type
6.4. By stage of development
6.5. By therapy area

Chapter 7 – Drug delivery dealmaking by technology type

7.1. Introduction
7.2. Deals by drug delivery type
Drug delivery
Bioavailability
Implantable
Oral delivery
Delayed release
Rapid release
Parenteral
Infusion
Injectable
Pro-drug
Targeted
Topical
Transdermal
Transmucosal
Buccal
Inhaled
Nasal
Ocular
Rectal
Sublingual
Urogenital
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering

See accompanying volume for:

Appendices

Introduction

Appendix 1 – Directory of drug delivery deals by company A-Z 2009-2014

Appendix 2 – Directory of drug delivery deals by stage of development 2009-2014

Appendix 3 – Directory of drug delivery deals by deal type 2009-2014

Appendix 4 – Directory of drug delivery deals by therapy area 2009-2014

Appendix 5 – Drug delivery partnering resource center
Online drug delivery partnering
Drug delivery partnering events
Further reading on drug delivery dealmaking

NA

 

Figure 1: Drug delivery partnering since 2009
Figure 2: Big pharma – top 50 – drug delivery deals 2009 to 2014
Figure 3: Big pharma drug delivery deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – drug delivery deals 2009 to 2014
Figure 5: Big biotech drug delivery deal frequency – 2009 to 2014
Figure 6: Active drug delivery dealmaking activity– 2009 to 2014
Figure 7: Drug delivery partnering by deal type since 2009
Figure 8: Drug delivery partnering by disease type since 2009
Figure 9: Drug delivery partnering by technology type since 2009
Figure 10: Drug delivery deals with a headline value by year- 2014
Figure 11: Drug delivery deals with a headline value by year- 2013
Figure 12: Drug delivery deals with a headline value by year- 2012
Figure 13: Drug delivery deals with a headline value by year- 2011
Figure 14: Drug delivery deals with a headline value by year- 2010
Figure 15: Drug delivery deals with a headline value by year- 2009
Figure 16: Summary median headline value by year, 2009-2014
Figure 17: Drug delivery deals with an upfront value by year- 2014
Figure 18: Drug delivery deals with an upfront value by year- 2013
Figure 19: Drug delivery deals with an upfront value by year- 2012
Figure 20: Drug delivery deals with an upfront value by year- 2011
Figure 21: Drug delivery deals with an upfront value by year- 2010
Figure 22: Drug delivery deals with an upfront value by year- 2009
Figure 23: Summary median upfront value by year, 2009-2014
Figure 24: Drug delivery deals with a milestone value by year- 2014
Figure 25: Drug delivery deals with a milestone value by year- 2013
Figure 26: Drug delivery deals with a milestone value by year- 2012
Figure 27: Drug delivery deals with a milestone value by year- 2011
Figure 28: Drug delivery deals with a milestone value by year- 2010
Figure 29: Drug delivery deals with a milestone value by year- 2009
Figure 30: Drug delivery deals with a royalty rate value by year- 2014
Figure 31: Drug delivery deals with a royalty rate value by year- 2013
Figure 32: Drug delivery deals with a royalty rate value by year- 2012
Figure 33: Drug delivery deals with a royalty rate value by year- 2011
Figure 34: Drug delivery deals with a royalty rate value by year- 2010
Figure 35: Drug delivery deals with a royalty rate value by year- 2009
Figure 36: Summary median royalty rate by year, 2009-2014
Figure 37: Components of the typical drug delivery deal structure
Figure 38: Best practice for drug delivery program development
Figure 39: Top drug delivery deals by value since 2009